Interim Report Q2 2025 Nanologica AB (publ)
10 July, 2025
No Comments
FINANCIAL SUMMARY Net sales for the second quarter amounted to SEK 2,335 thousand (2,174) and for the first half of
Investor relations (EN)
This is Nanologica
Nanologica is a Swedish life science tools company that provides consumables to pharmaceutical manufacturers. With a foundation in materials science and nanotechnology, we have developed an expertise in chromatography. Our products are used to purify pharmaceuticals during production using a technique called preparative chromatography.
We operate in a global niche market that is growing as a result of an increased demand for drugs for treating diabetes and obesity. Our silica-based purification media for preparative chromatography, NLAB Saga®, has been especially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for NLAB Saga®, it can increase productivity and reduce costs for pharmaceutical manufacturers.
Our mission is to increase access to cost-effective drugs through its purification products, and thereby enable more patients around the world access to life-saving treatments for diabetes and obesity.
Read more:
5 Reasons
to invest in Nanologica
By developing chromatography products that enable pharmaceutical manufacturers to streamline production and lower their production costs, Nanologica not only strives to create value for its shareholders, but also to contribute to more patients having access to adequate treatments.
Number of Shares and Votes in Nanologica AB (publ)
30 June, 2025
No Comments
The number of registered shares and votes in Nanologica AB has changed during the month of June following the registration
STATEMENT FROM THE BOARD OF DIRECTORS OF NANOLOGICA AB (PUBL) REGARDING THE MANDATORY BID FROM FLERIE INVEST AB
13 June, 2025
No Comments
The Board of Directors of Nanologica AB (publ) ("Nanologica" or the "Company") unanimously recommends the shareholders of Nanologica not to
Interim Report Q2 2025 Nanologica AB (publ)
10 July, 2025
No Comments
FINANCIAL SUMMARY Net sales for the second quarter amounted to SEK 2,335 thousand (2,174) and for the first half of
Delårsrapport Q2 2025 Nanologica AB (publ)
10 July, 2025
No Comments
FINANSIELL SAMMANFATTNING Nettoomsättningen för andra kvartalet uppgick till 2 335 TSEK (2 174) och för första halvåret till 13 087 TSEK
Interim Report Q1 2025 Nanologica AB (publ)
16 April, 2025
No Comments
FINANCIAL SUMMARY Net sales for the first quarter amounted to SEK 10,751 thousand (5,037) The operating loss amounted to SEK
Annual Report 2024
After many years of working with various technologies and products, Nanologica has developed into a pure chromatography company with products for purification of pharmaceuticals during production, on a global market. Today we provide pharmaceutical manufacturers with products that needed to manufacture fast-growing GLP-1 analogues and insulin. With these products and our expertise in method and application development, we can streamline our customers’ workflows and reduce their costs. This makes us relevant in a market characterized by both increasing volumes and an increased focus on costs.
Presentation of Nanologica
Follow this link for more video presentations and CEO interviews.
Company presentation made by CEO Andreas Bhagwani in June, 2023.
Investor Pitch Deck November 2024.
Please contact us at ir@nanologica.com for more information.
Subscribe to our news
For further information, please contact:
Johanna Johansson
Director IR, Communications and Marketing
